Skip to main
HUMA
HUMA logo

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte Inc. is positioning itself for significant commercial uptake and revenue growth through 2026 by scaling its manufacturing processes and enhancing hospital access to its bioengineered human tissues and organs. The company's advancements in trauma vascular repair bolster its credibility within both military and civilian healthcare markets, indicating a robust potential for market penetration and acceptance. Additionally, the validation of the durable performance of its biologic conduits in complex clinical situations further underscores the strength of Humacyte's pipeline and its capacity to address a wide range of healthcare needs, paving the way for future success in the biotechnology sector.

Bears say

Based on the information provided, Humacyte Inc. faces challenges that may hinder its stock performance, including a lack of proven market acceptance and potential regulatory hurdles associated with its innovative biotechnology platform. The company's extensive pipeline, while ambitious, may result in significant capital expenditures and prolonged timeframes for product development and commercialization, raising concerns about cash flow sustainability. Additionally, the competitive landscape for bioengineered tissues and organs is intense, which could impact Humacyte's ability to capture market share and achieve profitability.

Humacyte (HUMA) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Humacyte (HUMA) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.